Orakl Oncology Raises $34M Series A for Cancer Prediction
A patient sample carries a history that a cancer model needs to understand. Orakl Oncology builds its research platform around that connection, linking experiments on patient-derived tumor organoids with clinical information so drug developers can examine how a treatment might perform before committing to a trial.
The French company announced a $34M Series A co-led by Norrsken VC and Singular on November 12, 2026. The financing backs a larger biological dataset, expanded AI research and international development. For pharmaceutical teams, the proposition is earlier evidence for decisions that eventually determine which treatments reach patients, which groups enter a study and where research resources go.
What the Series A funds
Norrsken reports that the oversubscribed financing brings Orakl's total funding to $50M. The round includes InfraVia, Serena, the Patient Autonome Fund managed by Bpifrance, teampact.ventures and Plug and Play, alongside returning investors Verve Ventures, Speedinvest and HCVC. The official announcement uses dollar amounts without specifying their denomination; those figures are retained as reported.
Orakl plans to increase data generation 5x, expand from colorectal and pancreatic cancers into lung and gastric cancers, and establish teams in the US and UK. Those plans put a substantial share of the work around the model: more relevant experiments, broader disease coverage and closer relationships with pharmaceutical developers. Each expansion adds a practical question about the evidence required for a new research assignment.
There is earlier financing behind this round. A December 2024 report linked by Orakl described an €11M seed led by Singular. The euro-denominated seed and investor-reported dollar total should be read in their original terms, rather than assembled into an invented breakdown of equity, grants or other financing. The current announcement leaves valuation and the detailed capital mix undisclosed.
Why patient biology matters to the software
Orakl describes an experimental process that grows tumor organoids from patient material, tests drug responses and combines the resulting information with molecular measurements and longitudinal clinical histories. O-Predict supports development questions involving clinical endpoints, biomarkers and treatment combinations. O-Target addresses therapeutic target discovery, giving the platform a second research task beyond assessing a candidate's likely response.
That architecture gives the hospital and the laboratory an enduring role in product development. A model trained around these observations depends on how samples are obtained, how experiments are conducted and how the results remain connected to clinical context. Adding another data point has work attached to it. The commercial significance is that expanding useful coverage can require an expansion of biological operations alongside computational capacity.
Orakl reports 90% predictive accuracy across more than 30 clinical trials on its website. That is a company performance claim; the sources reviewed here do not establish independent validation of the methodology or a measured improvement in patient outcomes. A pharmaceutical scientist assessing the platform would still need to understand the population, endpoint and experimental setting behind any performance figure. The number starts a technical conversation whose relevance depends on the particular development program.
The buyer is choosing a research direction
A pharmaceutical customer has to decide what to do with a prediction. An encouraging response in an experimental system may support further investigation, while a different response pattern can raise questions about which patient group deserves attention. The value of a supplier like Orakl lies in whether its evidence is useful inside that decision, with enough context for the research team to interpret it.
That is a different commercial assignment from producing an impressive model demonstration. Buying teams must connect an external research result to the drug, indication and development decision already in front of them. As an analytical implication, repeat collaborations would give Orakl opportunities to learn how its evidence fits those decisions over time. Contract values, renewal rates and program-level economics remain undisclosed, so the financing offers no basis for calculating the return customers receive.
Norrsken says 18 of the world's top 20 pharmaceutical companies are in Orakl's commercial pipeline, and that initial engagements are becoming multi-year collaborations. Pipeline participation describes an opportunity rather than a completed sale. The distinction keeps the commercial picture legible while leaving the most useful development in view: some early relationships are growing into longer assignments. The identities and number of those customers were not established in the announcement.
A hospital spin-out takes on a wider operating map
Founded in 2023 as a Gustave Roussy spin-out, Orakl is led by CEO Fanny Jaulin, CTO Gustave Ronteix and COO Diane-Laure Pagès. Its current registered office is in Villejuif, France. The founders' combined responsibilities reflect a company whose work has to hold together across cancer biology, AI and the operations connecting research to patient-derived material.
The investment extends an established thesis. In its 2024 TechBio analysis, Speedinvest used Orakl as an example of combining clinical information and biological data to address cancer complexity. That historical perspective helps explain the continuity behind the current round. The newer financing broadens the resources and geographic reach available to pursue that approach, while bringing more investor relationships into the company.
For operators watching healthcare AI, Orakl makes an often-overlooked part of the product visible: the ability to keep generating relevant observations. The lab work, access to patient material and interpretation of results all affect what a pharmaceutical partner can ask next. As the founders expand into additional cancers and build teams abroad, an experiment in one part of that network will need to remain meaningful to the scientist deciding the next step of a drug program elsewhere.
Healthcare AI funding, last 30 days
DevCuration's funding database tracked 26 Healthcare AI rounds totaling $6.7B in disclosed capital over the past 30 days. Recent deals we covered:
- Vumedi Discloses $104M Series B for Physician AI LearningSeries B · $104M · Nov 22
- ODAIA Raises $15M Series C for Pharma Commercial IntelligenceSeries C · $15M · Nov 20
- Isomorphic Labs Raises $5B Series C for AI Drug DesignSeries C · $5B · Nov 18
- TestDynamics Secures $9M to Expand Imaging AI EvaluationSeries A · $9M · Nov 17
- Betterness Raises $1M to Expand Miami Wellness NetworksSeed Extension · $1M · Nov 16
Frequently Asked Questions
How does Orakl connect laboratory experiments with AI predictions?
Orakl grows patient-derived tumor organoids, tests their drug responses and connects the results with molecular measurements and clinical histories. Its AI uses that combined information to support oncology drug-development decisions.
What will the Series A change about Orakl’s research capacity?
Orakl plans to expand its dataset and AI research, increase data generation 5x, broaden coverage into lung and gastric cancers, and establish US and UK teams. These are announced plans rather than completed milestones.
Does Orakl’s pharma pipeline represent confirmed paying customers?
No. Norrsken reports that 18 of the top 20 pharmaceutical companies are in Orakl’s commercial pipeline and that initial engagements are becoming multi-year collaborations. The announcement does not disclose a paying-customer count or revenue.
What does Orakl’s reported prediction accuracy establish?
Orakl reports 90% accuracy across more than 30 trials. The reviewed sources do not establish independent validation of the methodology or a measured improvement in patient outcomes, so the figure should be read as a company-reported performance claim.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved

